Novavax Inc
NVAX6.830USD
-0.110-1.59%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
3.26P/E TTM
More Details of Novavax Inc Company
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Novavax Inc Info
Ticker SymbolNVAX
Company nameNovavax Inc
IPO dateMay 16, 1973
CEOJacobs (John C)
Number of employees952
Security typeOrdinary Share
Fiscal year-endMay 16
Address21 Firstfield Rd
CityGAITHERSBURG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20878
Phone12402682000
Websitehttps://www.novavax.com/?locale=US
Ticker SymbolNVAX
IPO dateMay 16, 1973
CEOJacobs (John C)
Company Executives of Novavax Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
38.91K
+10.82%
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
31.97K
--
Dr. Ruxandra Draghia-Akli, M.D., Ph.D.
Dr. Ruxandra Draghia-Akli, M.D., Ph.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
8.21K
--
Mr. James Patrick (Jim) Kelly
Mr. James Patrick (Jim) Kelly
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
38.91K
+10.82%
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Canada
575.67M
86.38%
Rest of the world
43.29M
6.50%
United States
39.41M
5.91%
Europe
8.09M
1.21%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.33%
Shah Capital Management, Inc.
8.24%
BlackRock Institutional Trust Company, N.A.
6.90%
State Street Investment Management (US)
4.43%
Sanofi SA
4.23%
Other
66.87%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.33%
Shah Capital Management, Inc.
8.24%
BlackRock Institutional Trust Company, N.A.
6.90%
State Street Investment Management (US)
4.43%
Sanofi SA
4.23%
Other
66.87%
Shareholder Types
Shareholders
Proportion
Investment Advisor
25.69%
Investment Advisor/Hedge Fund
20.96%
Hedge Fund
9.49%
Corporation
8.23%
Research Firm
4.30%
Pension Fund
0.65%
Bank and Trust
0.55%
Individual Investor
0.54%
Venture Capital
0.08%
Other
29.51%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
546
95.10M
58.55%
-6.89M
2025Q2
553
108.80M
66.99%
-11.74M
2025Q1
575
113.82M
70.29%
-16.33M
2024Q4
593
111.51M
69.72%
-5.93M
2024Q3
597
103.31M
64.96%
-4.25M
2024Q2
652
92.80M
65.79%
-10.97M
2024Q1
753
86.51M
64.06%
-11.91M
2023Q4
848
86.68M
74.23%
+6.21M
2023Q3
919
70.31M
60.51%
-6.00M
2023Q2
957
58.87M
62.55%
-19.22M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
15.40M
9.48%
-241.17K
-1.54%
Jun 30, 2025
Shah Capital Management, Inc.
11.51M
7.09%
+379.93K
+3.41%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.17M
6.88%
-388.58K
-3.36%
Jun 30, 2025
State Street Investment Management (US)
6.82M
4.2%
-214.91K
-3.05%
Jun 30, 2025
Sanofi SA
6.88M
4.24%
--
--
Jun 30, 2025
SK Bioscience Co., Ltd.
6.50M
4%
--
--
May 10, 2024
D. E. Shaw & Co., L.P.
3.94M
2.43%
+680.05K
+20.85%
Jun 30, 2025
Coatue Management, L.L.C.
3.84M
2.36%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
3.77M
2.32%
+4.34K
+0.12%
Jun 30, 2025
UBS Financial Services, Inc.
2.16M
1.33%
+850.71K
+64.76%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
ProShares Nanotechnology ETF
2.78%
iShares Genomics Immunology and Healthcare ETF
2.63%
Virtus LifeSci Biotech Products ETF
1.88%
ALPS Medical Breakthroughs ETF
0.55%
State Street SPDR S&P Biotech ETF
0.53%
First Trust Small Cap Value AlphaDEX Fund
0.51%
Direxion Daily S&P Biotech Bull 3X Shares
0.33%
First Trust Small Cap Core Alphadex Fund
0.19%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
View more
ProShares Nanotechnology ETF
Proportion2.78%
iShares Genomics Immunology and Healthcare ETF
Proportion2.63%
Virtus LifeSci Biotech Products ETF
Proportion1.88%
ALPS Medical Breakthroughs ETF
Proportion0.55%
State Street SPDR S&P Biotech ETF
Proportion0.53%
First Trust Small Cap Value AlphaDEX Fund
Proportion0.51%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.33%
First Trust Small Cap Core Alphadex Fund
Proportion0.19%
ProShares Ultra Nasdaq Biotechnology
Proportion0.13%
Invesco Nasdaq Biotechnology ETF
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Novavax Inc?
The top five shareholders of Novavax Inc are:
The Vanguard Group, Inc. holds 15.40M shares, accounting for 9.48% of the total shares.
Shah Capital Management, Inc. holds 11.51M shares, accounting for 7.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.17M shares, accounting for 6.88% of the total shares.
State Street Investment Management (US) holds 6.82M shares, accounting for 4.20% of the total shares.
Sanofi SA holds 6.88M shares, accounting for 4.24% of the total shares.
The Vanguard Group, Inc. holds 15.40M shares, accounting for 9.48% of the total shares.
Shah Capital Management, Inc. holds 11.51M shares, accounting for 7.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.17M shares, accounting for 6.88% of the total shares.
State Street Investment Management (US) holds 6.82M shares, accounting for 4.20% of the total shares.
Sanofi SA holds 6.88M shares, accounting for 4.24% of the total shares.
What are the top three shareholder types of Novavax Inc?
The top three shareholder types of Novavax Inc are:
The Vanguard Group, Inc.
Shah Capital Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Shah Capital Management, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Novavax Inc (NVAX)?
As of 2025Q3, 546 institutions hold shares of Novavax Inc, with a combined market value of approximately 95.10M, accounting for 58.55% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.44%.
What is the biggest source of revenue for Novavax Inc?
In FY2025Q1, the -- business generated the highest revenue for Novavax Inc, amounting to -- and accounting for --% of total revenue.
